La Jolla Pharma (LJPC) 9.40 $LJPC
Galectin Drug is a Fatty Liver Flop
at The Street - Tue Jul 29, 9:26AM CDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
La Jolla Pharmaceutical Company Closes Offering of Common Stock
Business Wire - Mon Jul 28, 5:29PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses.
4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jul 23, 8:14AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jul 22, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla.
La Jolla Pharmaceutical Company Analyst Initiation of Coverage: Steer Clear of this Company with a History of Failure by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
Will La Jolla (LJPC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:48AM CDT
Will La Jolla (LJPC) Continue to Surge Higher?
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
Business Wire - Tue Jul 15, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.
5 Stocks Breaking Out With Big Volume
at The Street - Mon Jul 14, 8:10AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
Business Wire - Tue Jul 08, 3:01PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the Company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH), a new indication. Initiation of this registration program is the result of a recent meeting between the Company and the U.S. Food and Drug Administration at which agreement was reached that blood pressure is an appropriate primary endpoint for approval.
La Jolla Pharmaceutical Company Strengthens Board of Directors with Appointment of Robert H. Rosen
Business Wire - Mon Jul 07, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the appointment of Robert H. Rosen to the Company's Board of Directors.
La Jolla Pharmaceutical Company Added to the Russell Microcap Index
Business Wire - Mon Jun 30, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27.
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 BIO International Convention
Business Wire - Thu Jun 19, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 BIO International Convention, taking place June 23-26 in San Diego, California.
La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Wed Jun 18, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 9th Annual JMP Securities Healthcare Conference taking place June 24-25 in New York City.
La Jolla Pharmaceutical Company Enters into Agreement With Stanford University for New Drug Delivery Technology
Business Wire - Mon Jun 16, 7:01AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has signed an option agreement with Leland Stanford Junior University ("Stanford" that will add proprietary technology to the Company's programs.
La Jolla Pharmaceutical Company Announces Completion of Enrollment of Phase 2 Extension Study of GCS-100 in Chronic Kidney Disease
Business Wire - Wed Jun 04, 3:00PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of GCS-100-CS-4003 ("4003 study" , its Phase 2 Extension study of GCS-100 in chronic kidney disease ("CKD" . The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study (GCS-100-CS-4002). A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year.
La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference
Business Wire - Wed May 28, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City.
La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress
Business Wire - Mon Mar 31, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla" , a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter and full-year 2014 financial results and highlights recent corporate progress.
La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin
Business Wire - Mon Mar 31, 7:01AM CDT
--Patent Covers Chronic Inflammatory Diseases including Chronic Kidney Disease and NASH
Galectin Drug is a Fatty Liver Flop
at The Street - Tue Jul 29, 9:26AM CDT
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
La Jolla Pharmaceutical Company Closes Offering of Common Stock
Business Wire - Mon Jul 28, 5:29PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters' option to purchase up to an additional 720,000 shares of common stock. Gross offering proceeds are approximately $56.6 million, including proceeds from the partial exercise of the underwriters' option to purchase additional shares, before deducting customary underwriting discounts and commissions and offering expenses. 4 Biotech Stocks Breaking Out on Big Volume
at The Street - Thu Jul 24, 8:25AM CDT
These biotech stocks rising on unusual volume are within range of triggering breakout trades.
La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jul 23, 8:14AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share. La Jolla has granted the underwriters a 30-day option to purchase up to an additional 720,000 shares of common stock. The offering is expected to close on or about July 28, 2014, subject to customary closing conditions. Jefferies LLC is acting as sole book-runner for the offering. Chardan Capital Markets, LLC, H.C. Wainwright & Co., LLC, LifeSci Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering. La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jul 22, 3:01PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by La Jolla. La Jolla Pharmaceutical Company Analyst Initiation of Coverage: Steer Clear of this Company with a History of Failure by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is a biopharmaceutical company focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer. The company's main product candidates include GCS-100 for the treatment of chronic kidney disease (CKD), LJPC-501 that is designed to help restore kidney function in patients with hepatorenal syndrome (HRS), and LJPC-401 for the treatment of iron disorders. In addition, LJPC is also developing LJPC-1010, which is an oral derivative of GCS-100 for the treatment of non-alcoholic steatohepatitis (NASH). Further, LJPC is also engaged in pre-clinical testing for LJPC-201 for hepatic fibrosis and LJPC-101 for end-stage renal disease (ESRD).
Will La Jolla (LJPC) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jul 16, 7:48AM CDT
Will La Jolla (LJPC) Continue to Surge Higher?
La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH)
Business Wire - Tue Jul 15, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial. 5 Stocks Breaking Out With Big Volume
at The Street - Mon Jul 14, 8:10AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Strength Seen in La Jolla Pharmaceutical Co. (LJPC): Stock Shoots 19% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jul 14, 7:44AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares surge 19% on the day.
La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension
Business Wire - Tue Jul 08, 3:01PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the Company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH), a new indication. Initiation of this registration program is the result of a recent meeting between the Company and the U.S. Food and Drug Administration at which agreement was reached that blood pressure is an appropriate primary endpoint for approval. La Jolla Pharmaceutical Company Strengthens Board of Directors with Appointment of Robert H. Rosen
Business Wire - Mon Jul 07, 7:00AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the appointment of Robert H. Rosen to the Company's Board of Directors. La Jolla Pharmaceutical Company Added to the Russell Microcap Index
Business Wire - Mon Jun 30, 7:01AM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27. La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 BIO International Convention
Business Wire - Thu Jun 19, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 BIO International Convention, taking place June 23-26 in San Diego, California. La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Wed Jun 18, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 9th Annual JMP Securities Healthcare Conference taking place June 24-25 in New York City. La Jolla Pharmaceutical Company Enters into Agreement With Stanford University for New Drug Delivery Technology
Business Wire - Mon Jun 16, 7:01AM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has signed an option agreement with Leland Stanford Junior University ("Stanford" that will add proprietary technology to the Company's programs. La Jolla Pharmaceutical Company Announces Completion of Enrollment of Phase 2 Extension Study of GCS-100 in Chronic Kidney Disease
Business Wire - Wed Jun 04, 3:00PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that it has completed enrollment of GCS-100-CS-4003 ("4003 study"
, its Phase 2 Extension study of GCS-100 in chronic kidney disease ("CKD" . The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study (GCS-100-CS-4002). A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year. La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference
Business Wire - Wed May 28, 3:30PM CDT
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City. La Jolla Pharmaceutical Company Announces Fourth-Quarter and Full-Year 2013 Financial Results and Highlights Recent Corporate Progress
Business Wire - Mon Mar 31, 3:30PM CDT
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the "Company" or "La Jolla"
, a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announces fourth-quarter and full-year 2014 financial results and highlights recent corporate progress. La Jolla Pharmaceutical Company Receives Patent Allowance Covering Broad Range of Modified Pectin
Business Wire - Mon Mar 31, 7:01AM CDT
--Patent Covers Chronic Inflammatory Diseases including Chronic Kidney Disease and NASH
